$Efficacy of infliximab in refractory ankylosing spondylitis: results of a six‐month open‐label study$

Efficacy of infliximab in refractory ankylosing spondylitis: results of a six‐month open‐label study

Objective. To evaluate the efficacy and safety of a loading regimen of the anti‐tumour necrosis factor α (TNF‐α) antibody infliximab in predominantly axial severe ankylosing spondylitis (AS). Methods. We enrolled in this study 50 patients (76% males, 87% HLA‐B27+, median age 35 yr, median disease du...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of rheumatology 2002-11, Vol.41 (11), p.1280-1285
Hauptverfasser:	Breban, M., Vignon, E., Claudepierre, P., Devauchelle, V., Wendling, D., Lespessailles, E., Euller‐Ziegler, L., Sibilia, J., Perdriger, A., Mezières, M., Alexandre, C., Dougados, M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Analysis of Variance Antibodies, Monoclonal - administration & dosage Biological and medical sciences Bones, joints and connective tissue. Antiinflammatory agents Dose-Response Relationship, Drug Drug Administration Schedule Female Follow-Up Studies France Humans Infliximab Infusions, Intravenous Male Medical sciences Middle Aged Pharmacology. Drug treatments Probability Prospective Studies Severity of Illness Index Spondylitis, Ankylosing - diagnosis Spondylitis, Ankylosing - drug therapy Statistics, Nonparametric Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!